Hunan Jiudian Pharmaceutical Co., Ltd.
SZSE:300705.SZ
24.47 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,930.677 | 2,692.511 | 2,326.216 | 1,627.665 | 978.159 | 924.061 | 801.375 | 534.515 | 376.4 | 290.492 | 266.489 | 241.413 |
| Cost of Revenue
| 784.398 | 621.788 | 516.981 | 349.901 | 246.023 | 300.547 | 323.679 | 256.915 | 183.088 | 140.316 | 128.018 | 108.699 |
| Gross Profit
| 2,146.28 | 2,070.724 | 1,809.235 | 1,277.764 | 732.136 | 623.514 | 477.696 | 277.6 | 193.312 | 150.177 | 138.472 | 132.714 |
| Gross Profit Ratio
| 0.732 | 0.769 | 0.778 | 0.785 | 0.748 | 0.675 | 0.596 | 0.519 | 0.514 | 0.517 | 0.52 | 0.55 |
| Reseach & Development Expenses
| 245.967 | 281.457 | 201.261 | 146.263 | 81.677 | 109.8 | 57.495 | 28.567 | 18.069 | 24.272 | 21.246 | 12.711 |
| General & Administrative Expenses
| 42.146 | 51.537 | 19.676 | 13.382 | 9.667 | 10.939 | 9.974 | 14.587 | 7.22 | 6.334 | 5.788 | 23.602 |
| Selling & Marketing Expenses
| 1,123.689 | 1,226.298 | 1,219.631 | 832.112 | 509.255 | 408.589 | 304.938 | 142.186 | 92.771 | 61.206 | 57.879 | 59.262 |
| SG&A
| 1,165.835 | 1,400.728 | 1,239.307 | 845.494 | 518.922 | 419.528 | 314.911 | 156.773 | 99.99 | 67.54 | 63.667 | 82.864 |
| Other Expenses
| 159.494 | -5.831 | -1.088 | 0.359 | -0.879 | -3.998 | -0.843 | 2.179 | 1.908 | 4.536 | 3.512 | 5.667 |
| Operating Expenses
| 1,571.296 | 1,676.354 | 1,487.48 | 1,020.502 | 624.987 | 551.658 | 396.718 | 199.926 | 131.432 | 103.369 | 95.573 | 105.712 |
| Operating Income
| 574.984 | 394.37 | 291.309 | 225.832 | 91.72 | 62.896 | 80.248 | 74.839 | 60.82 | 45.491 | 40.4 | 24.141 |
| Operating Income Ratio
| 0.196 | 0.146 | 0.125 | 0.139 | 0.094 | 0.068 | 0.1 | 0.14 | 0.162 | 0.157 | 0.152 | 0.1 |
| Total Other Income Expenses Net
| -2.79 | 7.791 | -1.088 | 0.359 | -0.879 | -3.998 | -0.843 | -3.378 | 1.836 | 4.034 | -1.212 | -8.292 |
| Income Before Tax
| 572.194 | 402.161 | 290.221 | 226.19 | 90.841 | 58.898 | 79.405 | 77.018 | 62.656 | 49.525 | 43.59 | 28.99 |
| Income Before Tax Ratio
| 0.195 | 0.149 | 0.125 | 0.139 | 0.093 | 0.064 | 0.099 | 0.144 | 0.166 | 0.17 | 0.164 | 0.12 |
| Income Tax Expense
| 59.817 | 33.9 | 20.52 | 21.944 | 8.581 | 3.832 | 7.42 | 8.445 | 8.128 | 4.882 | 5.804 | 3.723 |
| Net Income
| 512.377 | 368.261 | 269.7 | 204.246 | 82.26 | 55.066 | 71.985 | 68.573 | 54.527 | 44.643 | 37.793 | 25.268 |
| Net Income Ratio
| 0.175 | 0.137 | 0.116 | 0.125 | 0.084 | 0.06 | 0.09 | 0.128 | 0.145 | 0.154 | 0.142 | 0.105 |
| EPS
| 1.05 | 0.77 | 1.97 | 0.62 | 0.25 | 0.17 | 0.22 | 0.26 | 0.23 | 0.2 | 0.29 | 0.22 |
| EPS Diluted
| 1.04 | 0.76 | 1.97 | 0.62 | 0.25 | 0.17 | 0.22 | 0.26 | 0.23 | 0.2 | 0.29 | 0.22 |
| EBITDA
| 685.796 | 485.761 | 369.22 | 296.761 | 145.256 | 101.492 | 103.446 | 93.666 | 67.918 | 57.785 | 54.543 | 33.526 |
| EBITDA Ratio
| 0.234 | 0.18 | 0.159 | 0.182 | 0.148 | 0.11 | 0.129 | 0.175 | 0.18 | 0.199 | 0.205 | 0.139 |